164 related articles for article (PubMed ID: 9164001)
1. [Orphan drugs: problem of public health and economic stakes].
Brandissou S; Yagoubi N; Hasselot N
Therapie; 1996; 51(6):647-53. PubMed ID: 9164001
[TBL] [Abstract][Full Text] [Related]
2. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
3. [Orphan drugs: some legal, ethical and economics aspects].
Pabst JY
Rev Epidemiol Sante Publique; 2001 Sep; 49(4):387-96. PubMed ID: 11567205
[TBL] [Abstract][Full Text] [Related]
4. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
Liu BC; He L; He G; He Y
J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
[TBL] [Abstract][Full Text] [Related]
5. Developing treatments for inborn errors: incentives available to the clinician.
Haffner ME
Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
[TBL] [Abstract][Full Text] [Related]
6. Orphan drug legislation: lessons for neglected tropical diseases.
Villa S; Compagni A; Reich MR
Int J Health Plann Manage; 2009; 24(1):27-42. PubMed ID: 18435430
[TBL] [Abstract][Full Text] [Related]
7. Assessing the economic challenges posed by orphan drugs.
Drummond MF; Wilson DA; Kanavos P; Ubel P; Rovira J
Int J Technol Assess Health Care; 2007; 23(1):36-42. PubMed ID: 17234015
[TBL] [Abstract][Full Text] [Related]
8. [European ordinance on orphan drugs: changes and threats].
Linthorst GE; Hollak CE
Ned Tijdschr Geneeskd; 2003 Jan; 147(4):143-5. PubMed ID: 12635543
[TBL] [Abstract][Full Text] [Related]
9. [Orphan drugs in France (2001-2005): access to information and characteristics].
Baumevieille M; Daveluy A; Aulois-Griot M; Haramburu F
Therapie; 2007; 62(1):9-16. PubMed ID: 17374342
[TBL] [Abstract][Full Text] [Related]
10. [Orphan drugs].
Kolár J; Chalabala M; Srámková H
Ceska Slov Farm; 2001 Mar; 50(2):59-65. PubMed ID: 11288591
[TBL] [Abstract][Full Text] [Related]
11. [Orphan drugs--medications for patients with rare diseases].
Thielke D; Thyssen JP; Hansen BJ
Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
[TBL] [Abstract][Full Text] [Related]
12. [Orphan drugs].
Galeffi C
Ann Ist Super Sanita; 1991; 27(2):341-3. PubMed ID: 1661568
[TBL] [Abstract][Full Text] [Related]
13. [Orphan drugs: availability, reliability and reimbursement].
Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ
Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041
[TBL] [Abstract][Full Text] [Related]
14. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
15. Rare diseases, drug development, and AIDS: the impact of the Orphan Drug Act.
Arno PS; Bonuck K; Davis M
Milbank Q; 1995; 73(2):231-52. PubMed ID: 7776947
[TBL] [Abstract][Full Text] [Related]
16. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
17. Orphan drug development across Europe: bottlenecks and opportunities.
Heemstra HE; de Vrueh RL; van Weely S; Büller HA; Leufkens HG
Drug Discov Today; 2008 Aug; 13(15-16):670-6. PubMed ID: 18583178
[TBL] [Abstract][Full Text] [Related]
18. The challenges of orphan drugs and orphan diseases: real and imagined.
Hudson I; Breckenridge A
Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659
[TBL] [Abstract][Full Text] [Related]
19. [Orphan drugs and orphan diseases].
Campos-Castelló J
Rev Neurol; 2001 Aug 1-15; 33(3):216-20. PubMed ID: 11588712
[TBL] [Abstract][Full Text] [Related]
20. European Medicines Agency support mechanisms fostering orphan drug development.
Butlen-Ducuing F; Rivière F; Aarum S; Llinares-Garcia J
Drug News Perspect; 2010; 23(1):71-81. PubMed ID: 20155221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
